Figure 6
AURKA regulates FBXL7 expression through modulating its promoter activity. (a) Western blot and (b) quantitative reverse transcription–PCR (qRT–PCR) analysis were performed on AGS and BGC823 cells stably expressing shAURKA or shNC. Cells were cultured in the presence of 1 μg/ml doxycycline. Forty-eight hours after induction, cells were harvested and processed for immunoblotting and qRT–PCR. The experiments were repeated three times independently. Densitometry and qRT–PCR results were normalized against GAPDH protein and mRNA levels, respectively. Data are mean±s.d. of three independent experiment. (c and d) FBXL7 promoter activity in response to AURKA kinase inhibition and shRNA-mediated AURKA depletion. Promoter activities in response to dimethyl sulfoxide (DMSO) treatment or shNC were set as 100% and other activities are relative to this. Data present means±s.e.m. of three independent experiments and statistical analysis was performed with one-way ANOVA, *P⩽0.05; **P⩽0.01; ***P⩽0.001.
